Thermo Fisher Scientific Inc.
BVL:TMO 株式レポート
Thermo Fisher Scientific マネジメント Thermo Fisher Scientificの CEO はMarc Casperで、 Oct2009年に任命され、 の在任期間は 15.08年です。 の年間総報酬は$ 18.98Mで、 9.1%給与と90.9%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.041%を直接所有しており、その価値は$ 85.08M 。経営陣と取締役会の平均在任期間はそれぞれ5年と12.7年です。
主要情報 CEO給与比率 9.1% CEO在任期間 15.1yrs CEOの所有権 0.04% 経営陣の平均在職期間 5yrs 取締役会の平均在任期間 12.7yrs
経営陣の近況
Insider recently sold US$2.2m worth of stock Jul 30 Thermo Fisher Scientific Inc., Annual General Meeting, May 22, 2024 Apr 10
Thermo Fisher Scientific Appoints Srinath Venkatesh as Managing Director, India and South Asia Jan 24
Thermo Fisher Scientific Inc. Appoints Jennifer “Jenny” Johnson to the Audit Committee Sep 22 Thermo Fisher Scientific Inc. Elects Jenny Johnson to Board of Directors
すべての更新を表示
Third quarter dividend of US$0.39 announced Nov 12
Thermo Fisher Scientific Inc. Declares Quarterly Cash Dividend, Payable on January 15, 2025 Nov 08
Third quarter 2024 earnings released: EPS: US$4.27 (vs US$4.44 in 3Q 2023) Oct 24
Thermo Fisher Scientific Inc. Provides Earnings Guidance for the Year 2024 Oct 23
Thermo Fisher Scientific Introduces Fully Integrated Multimodal Analytical Scanning Transmission Electron Microscope to Advance Novel Research in Materials Science Oct 15
Thermo Fisher Scientific Introduces Mass Spectrometers to Simplify Trace Elemental Analysis and Enhance Productivity Oct 02 Thermo Fisher Scientific Inc. to Report Q3, 2024 Results on Oct 23, 2024
Upcoming dividend of US$0.39 per share Sep 06
FDA Grants Thermo Fisher Scientific Inc.'s SeCore HLA Typing Kit 510(k) Clearance for Use as Companion Diagnostic with a T-Cell Receptor Therapy for Synovial Sarcoma Aug 07 Thermo Fisher Scientific Inc. Announces Extended 510k Clearance of Freelite Assays for Evaluation of MGUS
Insider recently sold US$2.2m worth of stock Jul 30
Thermo Fisher Scientific Inc. Showcases Diagnostics Innovation Across Therapeutic Areas at ADLM 2024 Jul 26
Second quarter 2024 earnings released: EPS: US$4.05 (vs US$3.53 in 2Q 2023) Jul 25
Thermo Fisher Scientific Inc. Raises Earnings Guidance for the Year 2024 Jul 24
First quarter dividend of US$0.39 announced Jul 15 Thermo Fisher Scientific to Help Advance Myeloid Cancer Clinical Research and Treatment Utilizing Next Generation Sequencing Technology Thermo Fisher Scientific Inc. (NYSE:TMO) completed the acquisition of Olink Holding AB (publ) (NasdaqGM:OLK) from Summa Equity AB and others. Jul 10
Thermo Fisher Scientific Inc. to Report Q2, 2024 Results on Jul 24, 2024 Jul 04
Thermo Fisher Scientific Inc.(NYSE:TMO) dropped from Russell 1000 Growth-Defensive Index Jul 03
Thermo Fisher Scientific Introduces the Only Fully Automated Plasmid Purification System to Help Accelerate Discovery and Development of Therapies Jun 25
Thermo Fisher Scientific Introduces Thermo Scientific Heracell VIOS 250i AxD CO2 Incubators Jun 15
Upcoming dividend of US$0.39 per share Jun 10 Thermo Fisher Scientific Introduces Innovative Mass Spectrometer to Advance Clinical Research Jun 05
Thermo Fisher Scientific Updates Chromosomal Microarray Analysis Solutions to Comply with IVDR Regulation May 31
First quarter dividend of US$0.39 announced May 26
Thermo Fisher Scientific Inc. Declares Quarterly Dividend, Payable on July 15, 2024 May 23 Thermo Fisher Scientific Introduces Array-Based Solution for Extended Blood Type Research to Support Future Advancements Toward Safer Transfusions May 16
First quarter 2024 earnings released: EPS: US$3.48 (vs US$3.34 in 1Q 2023) Apr 24
Thermo Fisher Scientific Inc. Raises Revenue Guidance for the Full Year 2024 Apr 24 Thermo Fisher Scientific Inc. Introduces Animal Origin-Free Formulation to Support Scaling of Cell Therapy Manufacturing Apr 12
Thermo Fisher Scientific Inc., Annual General Meeting, May 22, 2024 Apr 10
Thermo Fisher Scientific Introduces Its Newest Line of High Performance, Ultra-Low Temperature (ULT) Freezers Apr 09
Thermo Fisher Scientific Inc. to Report Q1, 2024 Results on Apr 24, 2024 Apr 03
Thermo Fisher Scientific Announces A New In-Line Metrology Solution to Improve Battery Safety and Performance Mar 27
Thermo Fisher Scientific Inc. Launches Corevitas Clinical Registry in Generalized Pustular Psoriasis Mar 08
Upcoming dividend of US$0.39 per share Mar 07
New major risk - Share price stability Mar 05
Fourth quarter dividend increased to US$0.39 Feb 25
Thermo Fisher Scientific Inc. Increases Quarterly Cash Dividend, Payable on April 15, 2024 Feb 22
Thermo Fisher Scientific Inc. Launches New Ion Chromatography Instrument to Improve Reliability, Efficiency, and Functional Adaptability for Labs Feb 15
Thermo Fisher Scientific Expands GMP Laboratory Service Offerings with Biosafety Testing Including Mycoplasma Testing Feb 13
Full year 2023 earnings released: EPS: US$15.53 (vs US$17.73 in FY 2022) Feb 01
Thermo Fisher Scientific Inc. Announces Earnings Guidance for Full Year 2024 Jan 31
Thermo Fisher Scientific Appoints Srinath Venkatesh as Managing Director, India and South Asia Jan 24
Thermo Fisher Scientific Receives GMP Approval from the Italian Medicines Agency for its Manufacturing Facility of RNA-Based Products in Monza, Italy Jan 19
Thermo Fisher Scientific Inc. Announces Launch of Innovative Corevitas Pharmacovigilance Platform for Clinical Research Registries Dec 20
Investor sentiment improves as stock rises 17% Dec 20 Thermo Fisher Scientific Inc. Announces the Launch of the Thermo Scientific KingFisher Apex Dx and Applied Biosystems MagMAX Dx Viral/Pathogen NA Isolation Kit Dec 11
Upcoming dividend of US$0.35 per share at 0.3% yield Dec 08
Thermo Fisher Scientific Declares Quarterly Dividend, Payable on January 16, 202 Nov 10
New minor risk - Share price stability Nov 03 Thermo Fisher Scientific Announces New Fault Localization Solution for the Analysis of Advanced Logic Semiconductors Nov 01
Thermo Fisher Scientific Inc. Provides Earnings Guidance for the Year 2023 Oct 26
Third quarter 2023 earnings released: EPS: US$4.44 (vs US$3.81 in 3Q 2022) Oct 26
Thermo Fisher Scientific Inc. (NYSE:TMO) proposed an offer to acquire Olink Holding AB (publ) (NasdaqGM:OLK) from Summa Equity AB and others for approximately $3.3 billion. Oct 19
Thermo Fisher Scientific Inc. (NYSE:TMO) proposed an offer to acquire Olink Holding AB (publ) (NasdaqGM:OLK) from Summa Equity AB and others for approximately $3.3 billion. Oct 18
Thermo Fisher Scientific Inc. to Report Q3, 2023 Results on Oct 25, 2023 Oct 05
Thermo Fisher Scientific Inc. Appoints Jennifer “Jenny” Johnson to the Audit Committee Sep 22
Thermo Fisher Scientific Helps Accelerate Cell Therapy Manufacturing with A Next-Generation Platform of Gibco™ CTS™ Detachable Dynabeads™ Sep 07
Upcoming dividend of US$0.35 per share at 0.3% yield Sep 07
Thermo Fisher Scientific Announces the Launch of the EXENT Solution with IVDR Certification Aug 25
Thermo Fisher Scientific Introduces New Chromosomal Microarray with Two-Day Turnaround Time to Increase Lab Productivity Aug 23
Thermo Fisher Scientific Inc. (NYSE:TMO) acquired CorEvitas, LLC from Audax Management Company, LLC for approximately $910 million. Aug 15
Thermo Fisher Scientific Announces a New Line of Thermo Scientific TM TSG Series Refrigerators Aug 10
Thermo Fisher Scientific Inc. Revises earnings Guidance for 2023 Jul 27
Second quarter 2023 earnings released: EPS: US$3.53 (vs US$4.25 in 2Q 2022) Jul 27 Thermo Fisher Scientific Introduces New Reproductive Health Assays to Accelerate Fertility Research Jul 18
Thermo Fisher Scientific Inc. Elects Jenny Johnson to Board of Directors Thermo Fisher Scientific Inc. (NYSE:TMO) has entered into a definitive agreement to acquire CorEvitas, LLC from Audax Management Company, LLC for Approximately $910 million.
Thermo Fisher May Be Leading Bidder to Buy CorEvitas Jul 06 Thermo Fisher Scientific Announces Launch of Gibco™ OncoPro™ Tumoroid Culture Medium Kit Jun 29
Thermo Fisher Scientific Inc. (NYSE:TMO) completed the acquisition MarqMetrix, Inc. Jun 22
CEO報酬分析 Thermo Fisher Scientific の収益と比較して、Marc Casper の報酬はどのように変化したか？ 日付 総報酬 給与 会社業績 Sep 28 2024 n/a n/a US$6b
Jun 29 2024 n/a n/a US$6b
Mar 30 2024 n/a n/a US$6b
Dec 31 2023 US$19m US$2m US$6b
Sep 30 2023 n/a n/a US$6b
Jul 01 2023 n/a n/a US$6b
Apr 01 2023 n/a n/a US$6b
Dec 31 2022 US$28m US$2m US$7b
Oct 01 2022 n/a n/a US$7b
Jul 02 2022 n/a n/a US$7b
Apr 02 2022 n/a n/a US$8b
Dec 31 2021 US$21m US$2m US$8b
Oct 02 2021 n/a n/a US$9b
Jul 03 2021 n/a n/a US$9b
Apr 03 2021 n/a n/a US$8b
Dec 31 2020 US$26m US$2m US$6b
Sep 26 2020 n/a n/a US$5b
Jun 27 2020 n/a n/a US$4b
Mar 28 2020 n/a n/a US$4b
Dec 31 2019 US$19m US$2m US$4b
Sep 28 2019 n/a n/a US$4b
Jun 29 2019 n/a n/a US$4b
Mar 30 2019 n/a n/a US$3b
Dec 31 2018 US$19m US$1m US$3b
Sep 29 2018 n/a n/a US$3b
Jun 30 2018 n/a n/a US$2b
Mar 31 2018 n/a n/a US$2b
Dec 31 2017 US$22m US$1m US$2b
報酬と市場: Marcの 総報酬 ($USD 18.98M ) は、 PE市場 ($USD 5.66M ) の同規模の企業の平均を上回っています。
報酬と収益: Marcの報酬は、過去 1 年間の会社の業績と一致しています。
CEO（最高経営責任者 Mr. Marc N. Casper has been the Chief Executive Officer and President of Thermo Fisher Scientific, Inc. since October 15, 2009 and has been its Chairman of the Board of Directors since February 26, 2020. M ... Show more
リーダーシップ・チーム 名称 ポジション 在職期間 報酬 所有権 Chairman 15.1yrs US$18.98m 0.041% $ 85.1m Senior VP & CFO 9.3yrs US$6.24m 0.010% $ 21.9m Executive VP & COO 2.8yrs US$7.25m 0.0044% $ 9.3m Chief Human Resources Officer & Senior VP 7.7yrs US$2.89m 0.0035% $ 7.3m Executive Vice President no data US$5.73m 0.0044% $ 9.1m VP & Chief Accounting Officer 3.7yrs データなし 0.00041% $ 857.7k Senior VP & Chief Information Officer 5.3yrs データなし データなし Chief Scientific Officer 3.3yrs データなし データなし Vice President of Investor Relations no data データなし データなし Senior VP & General Counsel 6.8yrs US$3.12m 0.0032% $ 6.6m VP & Chief Communications Officer 4.1yrs データなし データなし Senior Vice President of Strategy & Corporate Development 4.6yrs データなし データなし
もっと見る
経験豊富な経営陣: TMOの経営陣は 経験豊富 であると考えられます ( 5年の平均在職年数)。
取締役 名称 ポジション 在職期間 報酬 所有権 Chairman 15.1yrs US$18.98m 0.041% $ 85.1m Independent Lead Director 18yrs US$403.12k 0.019% $ 39.4m Independent Director & Member of Scientific Advisory Board 12.7yrs US$325.72k 0.0022% $ 4.6m Independent Director 13.9yrs US$365.72k 0.0037% $ 7.8m Independent Director 8.5yrs US$345.72k 0.0024% $ 5.0m Member of Scientific Advisory Board no data US$9.40m データなし Member of Scientific Advisory Board & Director 15.5yrs US$345.72k 0.0022% $ 4.6m Member of Scientific Advisory Board 7yrs データなし データなし Member of Scientific Advisory Board no data データなし データなし Independent Director 5.2yrs US$345.72k 0.00040% $ 836.8k Member of Scientific Advisory Board no data データなし データなし Independent Director 7.7yrs US$353.19k 0.0012% $ 2.5m
もっと見る
経験豊富なボード: TMOの 取締役会 は経験豊富で 経験豊富 です ( 12.7年の平均在任期間)。
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}